OncoGenex Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACHV)

$1.28 -0.04 (-3.03 %)
(As of 12/13/2017 03:58 AM ET)
Previous Close$1.32
Today's Range$1.28 - $1.39
52-Week Range$1.25 - $10.23
Volume109,800 shs
Average Volume87,733 shs
Market Capitalization$16.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84

About OncoGenex Pharmaceuticals (NASDAQ:ACHV)

OncoGenex Pharmaceuticals logoAchieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27).

Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHV
CUSIP68230A10
Phone425-686-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio3.70%
Quick Ratio3.70%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.06 million
Price / Sales3.02
Cash FlowN/A
Price / CashN/A
Book Value$6.95 per share
Price / Book0.18

Profitability

Trailing EPS($5.30)
Net Income$-20,120,000.00
Net MarginsN/A
Return on Equity-126.78%
Return on Assets-101.46%

Miscellaneous

Employees17
Outstanding Shares11,950,000

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Frequently Asked Questions

What is OncoGenex Pharmaceuticals' stock symbol?

OncoGenex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHV."

How were OncoGenex Pharmaceuticals' earnings last quarter?

OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) posted its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter. View OncoGenex Pharmaceuticals' Earnings History.

When will OncoGenex Pharmaceuticals make its next earnings announcement?

OncoGenex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for OncoGenex Pharmaceuticals.

Who are some of OncoGenex Pharmaceuticals' key competitors?

Who are OncoGenex Pharmaceuticals' key executives?

OncoGenex Pharmaceuticals' management team includes the folowing people:

  • Richard Stewart, Chairman of the Board, Chief Executive Officer (Age 58)
  • Anthony Clarke, President, Chief Scientific Officer, Director (Age 61)
  • John A. Bencich, Chief Financial Officer, Chief Operating Officer, Executive Vice President (Age 39)
  • Cindy Jacobs M.D., Ph.D., Executive Vice President, Chief Medical Officer (Age 59)
  • Donald Joseph, Independent Director (Age 62)
  • Martin A. Mattingly Ph.D., Independent Director (Age 60)
  • Jay Moyes, Independent Director (Age 62)
  • H. Stewart Parker, Independent Director (Age 61)

How do I buy OncoGenex Pharmaceuticals stock?

Shares of OncoGenex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoGenex Pharmaceuticals' stock price today?

One share of OncoGenex Pharmaceuticals stock can currently be purchased for approximately $1.28.

How big of a company is OncoGenex Pharmaceuticals?

OncoGenex Pharmaceuticals has a market capitalization of $16.49 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-20,120,000.00 in net income (profit) each year or ($5.30) on an earnings per share basis. OncoGenex Pharmaceuticals employs 17 workers across the globe.

How can I contact OncoGenex Pharmaceuticals?

OncoGenex Pharmaceuticals' mailing address is 19820 NORTH CREEK PARKWAY, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-686-1500 or via email at [email protected]


MarketBeat Community Rating for OncoGenex Pharmaceuticals (ACHV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about OncoGenex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A2.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$2.00
Price Target Upside: N/AN/AN/A189.86% upside

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Consensus Price Target History

Price Target History for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2016Needham & Company LLCLower Price TargetBuy$6.00 -> $3.00N/AView Rating Details
1/21/2016Royal Bank of CanadaLower Price TargetSector Perform$1.60 -> $1.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Earnings History and Estimates Chart

Earnings by Quarter for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

OncoGenex Pharmaceuticals (NASDAQ ACHV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
11/9/2017Q3 2017($0.90)ViewN/AView Earnings Details
7/31/2017Q2 2017($0.10)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.29)($0.11)ViewN/AView Earnings Details
11/10/2016Q316($0.26)($0.12)ViewN/AView Earnings Details
8/4/2016Q216($0.22)($0.23)$1.17 million$2.10 millionViewN/AView Earnings Details
5/12/2016Q116($0.12)($0.12)$4.09 million$2.90 millionViewListenView Earnings Details
3/9/2016Q4($0.15)($0.06)$6.00 million$6.02 millionViewN/AView Earnings Details
11/12/2015Q3($0.17)($0.16)$5.97 million$6.74 millionViewListenView Earnings Details
8/13/2015Q2$0.34($0.26)$16.10 million$4.03 millionViewListenView Earnings Details
5/14/2015Q115($0.34)($0.20)$4.66 million$1.40 millionViewListenView Earnings Details
3/26/2015Q414($0.30)($0.27)$4.30 million$5.70 millionViewN/AView Earnings Details
10/30/2014($0.38)($0.23)$4.69 million$4.80 millionViewN/AView Earnings Details
8/7/2014($0.55)($0.47)$11.73 million$4.93 millionViewN/AView Earnings Details
4/30/2014($0.50)($0.59)$8.68 million$11.73 millionViewN/AView Earnings Details
3/11/2014Q113($0.66)($0.45)$10.20 million$8.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for OncoGenex Pharmaceuticals (NASDAQ:ACHV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

OncoGenex Pharmaceuticals (NASDAQ ACHV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.80%
Institutional Ownership Percentage: 4.01%
Insider Trades by Quarter for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

OncoGenex Pharmaceuticals (NASDAQ ACHV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016John BencichCFOSell1,380$0.57$786.60View SEC Filing  
6/13/2016Cindy JacobsCMOSell1,437$1.03$1,480.11View SEC Filing  
6/13/2016Scott Daniel CormackCEOSell4,856$1.03$5,001.68View SEC Filing  
3/15/2016Cindy JacobsCMOSell3,254$0.83$2,700.82View SEC Filing  
3/15/2016John BencichCFOSell834$0.83$692.22View SEC Filing  
3/15/2016Scott Daniel CormackCEOSell12,033$0.83$9,987.39View SEC Filing  
8/18/2015John BencichCFOSell1,427$2.76$3,938.52View SEC Filing  
6/12/2015Cindy JacobsCMOSell1,408$2.69$3,787.52View SEC Filing  
6/12/2015Scott Daniel CormackCEOSell4,571$2.69$12,295.99View SEC Filing  
5/20/2015Cindy JacobsCMOSell2,092$1.88$3,932.96View SEC Filing  
5/20/2015Scott Daniel CormackCEOSell7,543$1.88$14,180.84View SEC Filing  
8/13/2014Cindy JacobsCMOSell5,650$3.17$17,910.50View SEC Filing  
8/13/2014Scott Daniel CormackCEOSell18,341$3.17$58,140.97View SEC Filing  
3/17/2014Cindy JacobsCMOSell1,250$12.25$15,312.50View SEC Filing  
3/17/2014Scott Daniel CormackCEOSell4,634$12.25$56,766.50View SEC Filing  
8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.52View SEC Filing  
8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.16View SEC Filing  
3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.60View SEC Filing  
8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OncoGenex Pharmaceuticals (NASDAQ ACHV) News Headlines

Source:
DateHeadline
Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking CessationAchieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation
finance.yahoo.com - December 7 at 6:28 PM
ValuEngine Upgrades OncoGenex Pharmaceuticals (ACHV) to SellValuEngine Upgrades OncoGenex Pharmaceuticals (ACHV) to Sell
www.americanbankingnews.com - December 4 at 11:10 PM
OncoGenex Pharmaceuticals Inc. (ACHV) Announces  Earnings ResultsOncoGenex Pharmaceuticals Inc. (ACHV) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
Critical Survey: OncoGenex Pharmaceuticals (ACHV) & The CompetitionCritical Survey: OncoGenex Pharmaceuticals (ACHV) & The Competition
www.americanbankingnews.com - November 10 at 3:10 AM
Achieve Reports Financial Results for Third Quarter 2017Achieve Reports Financial Results for Third Quarter 2017
finance.yahoo.com - November 9 at 4:24 PM
Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017
finance.yahoo.com - November 8 at 5:23 PM
Achieve Announces Availability of Company Presentation from the Virtual Investor ConferenceAchieve Announces Availability of Company Presentation from the Virtual Investor Conference
finance.yahoo.com - November 6 at 4:09 PM
Financial Contrast: OncoGenex Pharmaceuticals (ACHV) and The CompetitionFinancial Contrast: OncoGenex Pharmaceuticals (ACHV) and The Competition
www.americanbankingnews.com - November 3 at 1:10 PM
Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017
finance.yahoo.com - October 30 at 3:29 PM
Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of CytisineAchieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
finance.yahoo.com - October 26 at 11:35 AM
CASI Pharmaceuticals (CASI) and OncoGenex Pharmaceuticals (ACHV) Critical ReviewCASI Pharmaceuticals (CASI) and OncoGenex Pharmaceuticals (ACHV) Critical Review
www.americanbankingnews.com - October 26 at 1:16 AM
Head to Head Review: OncoGenex Pharmaceuticals (ACHV) & The CompetitionHead to Head Review: OncoGenex Pharmaceuticals (ACHV) & The Competition
www.americanbankingnews.com - October 24 at 12:30 PM
Achieve Announces Advancement of Cytisine Clinical Development ProgramAchieve Announces Advancement of Cytisine Clinical Development Program
finance.yahoo.com - October 4 at 8:09 AM
BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2017 AGM and Awards Gala - Business Wire (press release)BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2017 AGM and Awards Gala - Business Wire (press release)
www.businesswire.com - September 23 at 8:40 PM
Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLCAchieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
finance.yahoo.com - September 14 at 8:24 PM
Achieve Announces Initiation of Cytisine Clinical Development ProgramAchieve Announces Initiation of Cytisine Clinical Development Program
finance.yahoo.com - August 16 at 3:24 PM
Albany Molecular Research (AMRI) & OncoGenex Pharmaceuticals (ACHV) Critical ComparisonAlbany Molecular Research (AMRI) & OncoGenex Pharmaceuticals (ACHV) Critical Comparison
www.americanbankingnews.com - August 15 at 6:08 PM
Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation TreatmentAchieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
finance.yahoo.com - August 10 at 4:51 PM
Affirmative Action Battle Has a New Focus: Asian-Americans - The ... - New York TimesAffirmative Action Battle Has a New Focus: Asian-Americans - The ... - New York Times
www.nytimes.com - August 4 at 12:47 PM

SEC Filings

OncoGenex Pharmaceuticals (NASDAQ:ACHV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OncoGenex Pharmaceuticals (NASDAQ:ACHV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OncoGenex Pharmaceuticals (NASDAQ ACHV) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.